Safety, Immunogenicity and Efficacy of Modified Vaccinia Ankara (MVA) Against Dryvax Challenge in Vaccinia-Naive and Vaccinia-Immune Individuals
02/2007
Journal Article
Authors:
Parrino, J.;
McCurdy, L.H.;
Larkin, B.D.;
Gordon, I.J.;
Rucker, S.E.;
Enama, M.E.;
Koup, R.A.;
Roederer, M.;
Bailer, R.T.;
Moodie, Z.;
Gu, L.;
Yan, L.;
Graham, B.S.;
Team, T.V.R.C. 201/20
Secondary:
Vaccine
Volume:
25
Pagination:
1513-1525
URL:
http://www.ncbi.nlm.nih.gov/pubmed/17126963
Keywords:
Antibody Formation/immunology; CD8-Positive T-Lymphocytes/immunology; Smallpox Vaccine/administration & dosage/adverse effects/immunology Vaccinia virus/immunology; Smallpox/prevention & control
Abstract:
Modified vaccinia Ankara (MVA) was evaluated as an alternative to Dryvax in vaccinia-naive and vaccinia-immune adult volunteers. Subjects received intramuscular MVA or placebo followed by Dryvax challenge at 3 months. Two or more doses of MVA prior to Dryvax reduced severity of lesion formation, decreased magnitude and duration of viral shedding, and augmented post-Dryvax vaccinia-specific CD8(+) T cell responses and extracellular enveloped virus protein-specific antibody responses. MVA vaccination is safe and immunogenic and improves the safety and immunogenicity of subsequent Dryvax vaccination supporting the potential for using MVA as a vaccine in the general population to improve immunity to orthopoxviruses.
